Imugene Historical Balance Sheet
IMU Stock | 0.04 0 5.41% |
Trend analysis of Imugene balance sheet accounts such as Other Current Liabilities of 23.5 M or Total Current Liabilities of 30.8 M provides information on Imugene's total assets, liabilities, and equity, which is the actual value of Imugene to its prevalent stockholders. By breaking down trends over time using Imugene balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Imugene latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Imugene is a good buy for the upcoming year.
Imugene Inventory |
|
Imugene |
About Imugene Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Imugene at a specified time, usually calculated after every quarter, six months, or one year. Imugene Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Imugene and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Imugene currently owns. An asset can also be divided into two categories, current and non-current.
Imugene Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Imugene assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Imugene books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Imugene balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Imugene are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most accounts from Imugene's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Imugene current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Imugene's Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 40.3 M in 2024, despite the fact that Other Stockholder Equity is likely to grow to (147.9 M).
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 673.4K | 553.5K | 1.5M | 1.6M | Total Assets | 147.6M | 197.1M | 151.4M | 159.0M |
Imugene balance sheet Correlations
Click cells to compare fundamentals
Imugene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Imugene balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 65.2M | 71.8M | 147.6M | 197.1M | 151.4M | 159.0M | |
Short Long Term Debt Total | 69.3K | 271.0K | 673.4K | 553.5K | 1.5M | 1.6M | |
Other Current Liab | 1.8M | 3.6M | 2.7M | 3.6M | 22.4M | 23.5M | |
Total Current Liabilities | 2.9M | 4.5M | 7.4M | 6.1M | 29.3M | 30.8M | |
Total Stockholder Equity | 59.8M | 65.0M | 138.7M | 189.6M | 118.3M | 124.2M | |
Property Plant And Equipment Net | 155.6K | 466.0K | 862.8K | 683.0K | 1.7M | 1.8M | |
Current Deferred Revenue | 390.6K | 738.3K | 1.3M | 1.6M | 1.9M | 2.0M | |
Net Debt | (30.0M) | (29.2M) | (99.2M) | (152.6M) | (91.6M) | (87.0M) | |
Retained Earnings | (47.3M) | (65.7M) | (103.5M) | (141.4M) | (289.8M) | (275.3M) | |
Accounts Payable | 1.0M | 759.7K | 4.5M | 2.3M | 6.0M | 6.3M | |
Cash | 30.1M | 29.5M | 99.9M | 153.2M | 93.1M | 97.8M | |
Non Current Assets Total | 30.7M | 35.5M | 33.8M | 31.4M | 38.4M | 40.3M | |
Cash And Short Term Investments | 30.1M | 29.5M | 99.9M | 153.2M | 94.5M | 99.3M | |
Net Receivables | 4.2M | 6.7M | 12.8M | 12.1M | 12.6M | 13.2M | |
Common Stock Shares Outstanding | 4.1B | 4.7B | 5.6B | 6.3B | 7.1B | 7.4B | |
Liabilities And Stockholders Equity | 65.2M | 71.8M | 147.6M | 197.1M | 151.4M | 159.0M | |
Non Current Liabilities Total | 2.5M | 2.3M | 1.5M | 1.4M | 3.8M | 4.0M | |
Other Stockholder Equity | (45.5M) | (1.0) | (127.3M) | (173.0M) | (155.7M) | (147.9M) | |
Total Liab | 5.4M | 6.8M | 8.9M | 7.4M | 33.1M | 34.8M | |
Property Plant And Equipment Gross | 155.6K | 718.9K | 1.3M | 1.0M | 2.6M | 2.8M | |
Total Current Assets | 34.5M | 36.3M | 113.8M | 165.7M | 113.0M | 118.7M | |
Accumulated Other Comprehensive Income | 14.3M | 17.6M | 11.4M | 16.7M | 37.8M | 39.7M | |
Short Term Debt | 60.9K | 106.0K | 184.2K | 191.1K | 912.5K | 958.1K | |
Intangible Assets | 30.5M | 34.9M | 32.7M | 30.5M | 34.1M | 35.8M | |
Common Stock | 92.8M | 113.1M | 230.8M | 314.4M | 370.3M | 388.8M | |
Other Liab | 2.5M | 2.2M | 987.1K | 990.6K | 1.1M | 1.1M | |
Net Tangible Assets | 29.3M | 30.1M | 106.0M | 159.1M | 183.0M | 192.2M | |
Long Term Investments | 80.6K | 115.2K | 252.4K | 217.6K | 2.4M | 2.5M | |
Property Plant Equipment | 155.6K | 466.0K | 862.8K | 683.0K | 614.7K | 645.4K | |
Other Current Assets | 194.1K | 170.1K | 1.1M | 401.6K | 5.9M | 6.2M | |
Long Term Debt Total | 8.4K | 165.0K | 489.3K | 362.4K | 326.2K | 462.4K | |
Net Invested Capital | 59.8M | 65.0M | 138.7M | 188.4M | 118.3M | 85.8M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.